{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T15:02:49Z","timestamp":1793026969916,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Respiratory syncytial virus (RSV) is a common viral infection with the potential for severe illness in infants, leading to thousands of pediatric hospitalizations annually. In late 2023, Beyfortus (nirsevimab), a long-acting monoclonal antibody, became available to provide passive RSV immunization for all newborns meeting eligibility criteria. This study aimed to explore parental decision-making regarding RSV immunization, particularly in comparison to family uptake of COVID-19 and influenza vaccines, within an urban, predominantly Medicaid population in North Philadelphia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This qualitative study was conducted at Temple University Hospital and Temple Pediatric Care outpatient clinic. Semi-structured interviews were performed with 25 parents and primary caregivers of newborns who received RSV immunization during the 2023\u20132024 season. Participants were recruited from a retrospective list and interviewed by phone using a standardized questionnaire. Grounded Theory methodology was applied for data analysis using iterative coding to identify themes related to immunization perceptions and acceptance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Participants expressed high levels of trust in healthcare providers and prioritized safety and efficacy when making immunization decisions. Parents accepted RSV immunization due to personal or family experiences with RSV, general desire to protect their newborns, or pediatrician recommendation. In contrast, COVID-19 and influenza vaccine decisions were less consistent. Concerns about side effects and perceived lack of effectiveness were common reasons for declining COVID-19 vaccines, despite similar motivations for protection. Social media and political beliefs had minimal reported influence. Parents reported a lack of consistent, reliable online sources for vaccine information, often relying on general internet searches. Many misunderstood immunization\/vaccine efficacy, equating it with complete immunity rather than reduced disease severity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Parental acceptance of RSV immunization was driven by protective instincts for newborns and familiarity with RSV as a disease. Hesitancy toward COVID-19 vaccination stemmed largely from concerns about effectiveness and confusion around immunization\/vaccine purpose. Trust in medical professionals influenced decision-making, though participants lacked a consistent source of immunization information. Improved public education on immunization efficacy and centralized access to trustworthy information may enhance immunization uptake and address ongoing hesitancy across all pediatric immunizations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12887-025-05889-x","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T06:56:06Z","timestamp":1752648966000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Newborn RSV immunization rates and reasons compared to family COVID-19 and influenza immunization status"],"prefix":"10.1186","volume":"25","author":[{"given":"Joshua","family":"Somers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Aronoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Tuohy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"5889_CR1","unstructured":"Centers for Disease Control and Prevention. Young children and respiratory viruses. Atlanta (GA): CDC. 2023. https:\/\/www.cdc.gov\/respiratory-viruses\/risk-factors\/young-children.html. Accessed 2025 Mar 1."},{"issue":"9","key":"5889_CR2","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJMoa2110275","volume":"386","author":"LL Hammitt","year":"2022","unstructured":"Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837\u201346.","journal-title":"N Engl J Med"},{"issue":"11","key":"5889_CR3","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.3390\/vaccines10111968","volume":"10","author":"SH Baumer-Mouradian","year":"2022","unstructured":"Baumer-Mouradian SH, Hart RJ, Visotcky A, Fraser R, Prasad S, Levas M, et al. Understanding influenza and SARS-CoV-2 vaccine hesitancy in racial and ethnic minority caregivers. Vaccines. 2022;10(11):1968. https:\/\/doi.org\/10.3390\/vaccines10111968.","journal-title":"Vaccines"},{"issue":"46","key":"5889_CR4","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.1016\/j.vaccine.2022.09.090","volume":"40","author":"A Byrne","year":"2022","unstructured":"Byrne A, Thompson LA, Filipp SL, Ryan K. COVID-19 vaccine perceptions and hesitancy amongst parents of school-aged children during the pediatric vaccine rollout. Vaccine. 2022;40(46):6680\u20137.","journal-title":"Vaccine"},{"issue":"6","key":"5889_CR5","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1177\/00333549221114346","volume":"137","author":"JB Ruiz","year":"2022","unstructured":"Ruiz JB, Bell RA. Parental COVID-19 vaccine hesitancy in the United States. Public Health Rep. 2022;137(6):1162\u20139.","journal-title":"Public Health Rep"},{"issue":"1\u20132","key":"5889_CR6","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s10865-022-00316-3","volume":"46","author":"JA Manganello","year":"2023","unstructured":"Manganello JA, Chiang SC, Cowlin H, Kearney MD, Massey PM. HPV and COVID-19 vaccines: social media use, confidence, and intentions among parents living in different community types in the United States. J Behav Med. 2023;46(1\u20132):212\u201328.","journal-title":"J Behav Med"},{"key":"5889_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2311476","author":"HB Fontenot","year":"2024","unstructured":"Fontenot HB, Quist KM, Glauberman G, Michel A, Zimet G. Impact of the COVID-19 pandemic on social media utilization, influences related to parental vaccine decision-making, and opinions on trustworthy social media vaccination campaigns: a qualitative analysis. Hum Vaccin Immunother. 2024. https:\/\/doi.org\/10.1080\/21645515.2024.2311476.","journal-title":"Hum Vaccin Immunother"},{"issue":"23","key":"5889_CR8","doi-asserted-by":"publisher","first-page":"126050","DOI":"10.1016\/j.vaccine.2024.06.018","volume":"42","author":"S Langer","year":"2024","unstructured":"Langer S, Holzapfel S, August L, Badura A, Wellmann S, Mack I. Parental knowledge and attitudes to infant immunization in the context of RSV: all about confidence? Vaccine. 2024;42(23):126050. https:\/\/doi.org\/10.1016\/j.vaccine.2024.06.018.","journal-title":"Vaccine"},{"issue":"10","key":"5889_CR9","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1080\/14760584.2022.2108799","volume":"21","author":"G Lee Mortensen","year":"2022","unstructured":"Lee Mortensen G, Harrod-Lui K. Parental knowledge about respiratory syncytial virus (RSV) and attitudes to infant immunization with monoclonal antibodies. Expert Rev Vaccines. 2022;21(10):1523\u201331.","journal-title":"Expert Rev Vaccines"},{"key":"5889_CR10","doi-asserted-by":"publisher","first-page":"105658","DOI":"10.1016\/j.earlhumdev.2022.105658","volume":"173","author":"AFS Da Cunha","year":"2022","unstructured":"Da Cunha AFS, de Brito Brand\u00e3o M, Bensemann Gontijo AP, Marques de Miranda D, Vaz de Melo Mambrini J, Cotta Mancini M. Parental priorities in the home care of preterm and full-term newborns. Early Hum Dev. 2022;173:105658. https:\/\/doi.org\/10.1016\/j.earlhumdev.2022.105658.","journal-title":"Early Hum Dev"},{"issue":"1","key":"5889_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12913-019-4017","volume":"19","author":"E Sarin","year":"2019","unstructured":"Sarin E, Maria A. Acceptability of a family-centered newborn care model among providers and receivers of care in a public health setting: a qualitative study from India. BMC Health Serv Res. 2019;19(1):184. https:\/\/doi.org\/10.1186\/s12913-019-4017.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"5889_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1370\/afm.2632","volume":"19","author":"M Bazargan","year":"2021","unstructured":"Bazargan M, Cobb S, Assari S. Discrimination and medical mistrust in a racially and ethnically diverse sample of California adults. Ann Fam Med. 2021;19(1):4\u201315.","journal-title":"Ann Fam Med"},{"key":"5889_CR13","unstructured":"American Academy of Pediatrics. FDA approves nirsevimab to prevent RSV in infants. Itasca (IL), AAP News. 2023. https:\/\/publications.aap.org\/aapnews\/news\/25085\/FDA-approves-nirsevimab-to-prevent-RSV-in-infants. Accessed 2025 Mar 14."},{"key":"5889_CR14","unstructured":"U.S. Food and Drug Administration. FDA approves new drug to prevent RSV in babies and toddlers. Silver Spring (MD): FDA; 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-prevent-rsv-babies-and-toddlers. Accessed 2025 Mar 14."},{"issue":"4","key":"5889_CR15","doi-asserted-by":"publisher","first-page":"e13292","DOI":"10.1111\/irv.13292","volume":"18","author":"B Nunes","year":"2024","unstructured":"Nunes B, Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, Moustsen-Helms IR, Sacco C, Fabiani M, Castilla J, Mart\u00ednez-Baz I, Meijerink H, Machado A, Soares P, Ljung R, Pihlstr\u00f6m N, Nardone A, Bacci S, Monge S, VEBIS-EHR working group. Effectiveness of the XBB.1.5 COVID-19 vaccines against SARS-CoV-2 hospitalisation among adults aged\u2009\u2265\u200965 years during the BA.2.86\/JN.1 predominant period, VEBIS hospital study, europe, November 2023 to May 2024. Influenza Other Respir Viruses. 2024;18(4):e13292. https:\/\/doi.org\/10.1111\/irv.13292.","journal-title":"Influenza Other Respir Viruses"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-05889-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-025-05889-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-05889-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T11:41:46Z","timestamp":1757245306000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-025-05889-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5889"],"URL":"https:\/\/doi.org\/10.1186\/s12887-025-05889-x","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board at Temple University (IRB No. 31445, approved on July 10, 2024). Verbal consent was obtained from all participants prior to data collection, and confidentiality of all responses was maintained throughout the study. Research carried out in this study was in compliance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"555"}}